9 June 2021 in Cancer Science
TTthe Working Group for Genitourinary Tumors
the Working Group for Genitourinary Tumors
+7
There are no clinical reports of long‐term follow‐up after carbon‐ion radiotherapy (CIRT) using a dose of 51.6 Gy (relative biological effectiveness [RBE]) in 12 fractions for localized prostate cancer, or of a comparison of clinical outcomes between passive and scanning beam irradiation. A total of 256 patients with localized prostate cancer who received CIRT at a dose of 51.6 Gy (RBE) in 12 fractions using two different beam delivery techniques (passive [n = 45] and scanning [n = 211]), and who were followed for more than 1 year, were analyzed. The biochemical relapse‐free (bRF) rate was defined by the Phoenix definition, and the actuarial toxicity rates were evaluated using the Kaplan‐Meier method. Of the 256 patients, 41 (16.0%), 111 (43.4%), and 104 (40.6%) were classified as low, intermediate, and high risk, respectively, after a median follow‐up of 7.0 (range 1.1‐10.4) years. Androgen deprivation therapy was performed in 212 patients (82.8%). The 5‐year bRF rates of the low‐, intermediate‐, and high‐risk patients were 95.1%, 90.9%, and 91.1%, respectively. The 5‐year rates of grade 2 late gastrointestinal and genitourinary toxicities in all patients were 0.4% and 6.3%, respectively. No grade ≥3 toxicities were observed. There were no significant differences in the rates of bRF or grade 2 toxicities in patients who received passive irradiation versus scanning irradiation. Our long‐term follow‐up results showed that a CIRT regimen of 51.6 Gy (RBE) in 12 fractions for localized prostate cancer yielded a good therapeutic outcome and low toxicity rates irrespective of the beam delivery technique.
11 February 2025 in Journal of Applied Clinical Medical Physics
This study aimed to compare the treatment plans of x‐ray SBRT and scanning carbon ion radiation therapy (CIRT) for localized lung tumors, and to evaluate the dose dependence of tumor size tumor‐to‐heart distance. For phantom verification, we used a chest phantom with a spherical simulated tumor. Treatment plans for 3‐dimensional conformal radiation therapy (3D‐CRT), volumetric modulated arc therapy (VMAT), and CIRT were created. GTVs were created in sizes ranging from 0.5 to 5 cm in diameter, and the dependence of the lung dose on GTV diameter was evaluated for each treatment plan. For patient validation, 30 cases of localized lung tumors were analyzed. 3D‐CRT, VMAT, and CIRT treatment plans were developed, and DVH parameters were evaluated for each GTV size and GTV‐to‐heart distance. In both phantom and patient validations, the OAR doses were the lowest for CIRT. The lung dose increased with increasing GTV diameter for all three treatment plans. CIRT had the smallest ratio of lung dose increase to GTV diameter increase among the three treatment plans. Heart dose in CIRT was independent of GTV size and GTV‐to‐heart distance Conclusions: The results of the present study suggested that the use of scanning CIRT can reduce the OAR dose while guaranteeing the tumor dose compared to x‐ray SBRT. In addition, it was suggested that CIRT can treat patients with large GTV sizes while maintaining low lung and heart dose.
18 February 2025 in Journal of Applied Clinical Medical Physics
The thermoluminescence dosimeter (TLD) sheet is a measurement device coated with manganese‐doped LiB3O5 in sheet form. The sheet is 0.2‐mm thick and flexible. Hence, it can fit and be installed on irregular surfaces. The current study aimed to evaluate the feasibility of measuring patient surface doses during radiation therapy using TLD sheets. Further, the surface doses when using a three‐dimensional (3D) printed bolus were compared. First, calibration of the between TLD sheet measurements and the irradiation doses was performed. Second, dose calculations and TLD sheet measurements were compared to evaluate the error between treatment planning system (TPS) dose calculations and surface dose measurements. Finally, the TLD sheet was fitted to the head phantom to measure the surface dose at the uneven areas under two conditions (with a commercial [CM] bolus and a 3D‐printed bolus). Based on the error from the dose calculation algorithm and the difference between the TLD sheet thickness and the dose grid size or evaluation structure volume, the differences between the TLD sheet measurements and the treatment plan doses were up to 68.6% for the X‐ray collapsed cone convolution (CCC) method and up to 8.4% for the electron beam Monte Carlo (MC) method. Based on the results of the surface dosimetry of the head phantom, the application of surface dosimetry, particularly skin dosimetry, even on uneven body surfaces, can be feasible.
20 November 2026 in Journal of Radiation Research
This study aimed to evaluate the efficacy and safety of particle therapy (PT) for kidney cancer by analyzing data from a multicenter registry study and comparing outcomes with those of stereotactic body radiation therapy (SBRT) through a systematic review and meta-analysis. Patients with kidney cancer who received PT between May 1, 2016 and October 31, 2022, were identified from the Proton Net for proton beam therapy (PBT) and J-CROS for carbon-ion radiotherapy (CIRT). The assessed outcomes included overall survival (OS), progression-free survival (PFS), local control (LC), incidence of grade ≥ 3 late adverse events (AEs) and changes in the estimated glomerular filtration rate (eGFR) at 3 years after PT. Fifty-nine patients (median age 71 years) were analyzed, including 15 (25%) with tumors >40 mm in diameter. The median follow-up was 44.3 months. The 3-year OS, PFS and LC were 92.0%, 82.7% and 94.6%, respectively. The 3-year incidence of treatment-related grade ≥ 3 late AE was 0%. The median change in eGFR at 3 years was −12.0 mL/min/1.73 m2 (range, −38.2 to +5.9). The systematic review identified 14 eligible studies. In the meta-analysis, the 3-year OS was significantly higher in the PT group than in the SBRT group (92.4% vs 79.2%, P = 0.0175) in an unadjusted indirect comparison, while no significant differences were found for other outcomes. A critical risk of bias due to confounding details and the limited number of patients preclude definitive comparative conclusions; and future prospective studies are warranted, particularly for large tumors for which SBRT becomes challenging.
13 March 2024 in Journal of Applied Clinical Medical Physics
Background: This study aimed to evaluate the clinical acceptability of rotational gantry‐based single‐position carbon‐ion radiotherapy (CIRT) to reduce the gastrointestinal (GI) dose in pancreatic cancer. We also evaluated the usefulness of the deformable image registration (DIR)‐based dosimetry method for CIRT.Material and methods: Fifteen patients with pancreatic cancer were analyzed. The treatment plans were developed for four beam angles in the supine (SP plan) and prone (PR plan) positions. In the case of using multiple positions, the treatment plan was created with two angles for each of the supine and prone position (SP + PR plan). Dose evaluation for multiple positions was performed in two ways: by directly adding the values of the DVH parameters for each position treatment plan (DVH sum), and by calculating the DVH parameters from the accumulative dose distribution created using DIR (DIR sum). The D2cc and D6cc of the stomach and duodenum were recorded for each treatment plan and dosimetry method and compared.Results: There were no significant differences among any of the treatment planning and dosimetry methods (p > 0.05). The DVH parameters for the stomach and duodenum were higher in the PR plan and SP plan, respectively, and DVH sum tended to be between the SP and PR plans. DVH sum and DIR sum, DVH sum tended to be higher for D2cc and DIR sum tended to be higher for D6cc.Conclusion: There were no significant differences in the GI dose, which suggests that treatment with a simple workflow performed in one position should be clinically acceptable. In CIRT, DIR‐based dosimetry should be carefully considered because of the potential for increased uncertainty due to the steep dose distributions.
23 June 2021 in Journal of Radiation Research
When this paper first published online, the author name Rei Mastueda was incorrect. It should have been Rei Matsueda. This has now been corrected online.